-Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA Cardiac Clamp.
Tuesday, January 2, 2024
SenesTech Signs Expanded Distribution Agreement for Evolve™ Soft Bait Sales
SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations, today announces the expansion of its distribution agreement with Pesterminators Pvt Ltd to include the deployment of EvolveTM. This expansion also extends the territory into the United Arab Emirates (UAE) market through the Pesterminators subsidiary, TCS Global for General Trading LLC in UAE.
Better Therapeutics Eyes Breakthrough Designation for Digital Therapeutic Platform for Liver Disease
-Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NAFLD and NASH.
Athira Pharma 10% owner Perceptive Advisors discloses buy
Athira Pharma (NASDAQ:ATHA) 10% owner Perceptive Advisors disclosed the purchase of 605,686 shares for a transaction value of $1,462,896.
Akari $2 Million Private Placement from Current Investors
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.
In connection with the financing, Akari issued 947,868 unregistered American Depository Shares (“ADSs”), each representing 2,000 of the company’s ordinary shares, at a purchase price of $2.11 per ADS.
KalVista Pharmaceuticals says Venrock Healthcare buys
KalVista Pharmaceuticals saw insider buying activity with Venrock Healthcare Capital Partners purchasing over 500K shares
Subscribe to:
Posts (Atom)